Drug profile · INN
voriconazole
VFEND
voriconazole (VFEND) is a cytochrome p450 51 inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: iv (infusion). Current US regulatory status: approved.
Drug details — voriconazole
- US status
- approved
- Class
- Antiinfectives for systemic use (J02)
- Route
- IV (INFUSION)
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
voriconazole (VFEND) is a cytochrome p450 51 inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: iv (infusion). Current US regulatory status: approved.
Key facts
Mechanism of action
Cytochrome P450 51 inhibitor
Primary target: Lanosterol 14-alpha demethylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is voriconazole?
voriconazole (VFEND) is a cytochrome p450 51 inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: iv (infusion). Current US regulatory status: approved.
What is the brand name for voriconazole?
VFEND is a marketed brand name for voriconazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of voriconazole?
voriconazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.